Wave Life Sciences: Revolutionizing Obesity & Rare Disease Treatments

Wave Life Sciences unveils promising updates on their pipeline, with WVE-007 targeting obesity. Phase one data shows significant reductions in visceral and total fat in healthy individuals with average BMI of thirty-two. The company plans to launch phase two trials this quarter, exploring combo studies with incretins and maintenance after stopping other drugs. WVE-006 for alpha-one antitrypsin deficiency shows therapeutic AAT protein levels over twenty micromolar during inflammation. Waves approach edits RNA in the liver for both lung and liver benefits, with potential to reshape treatments for obesity and rare diseases. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/aa79c824efd7b913